9.87
0.12 (1.23%)
| Previous Close | 9.75 |
| Open | 9.74 |
| Volume | 591,459 |
| Avg. Volume (3M) | 1,076,388 |
| Market Cap | 1,045,084,928 |
| Price / Sales | 3.91 |
| Price / Book | 2.05 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -277.30% |
| Operating Margin (TTM) | -435.71% |
| Diluted EPS (TTM) | -4.23 |
| Quarterly Revenue Growth (YOY) | -80.70% |
| Total Debt/Equity (MRQ) | 15.25% |
| Current Ratio (MRQ) | 5.37 |
| Operating Cash Flow (TTM) | -300.00 M |
| Levered Free Cash Flow (TTM) | -174.00 M |
| Return on Assets (TTM) | -22.25% |
| Return on Equity (TTM) | -63.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arcus Biosciences, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 34.93% |
| % Held by Institutions | 64.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gilead Sciences, Inc. | 31 Dec 2024 | 30,061,124 |
| Invus Financial Advisors, Llc | 30 Jun 2024 | 1,612,077 |
| Boxer Capital, Llc | 30 Sep 2024 | 1,602,200 |
| Boxer Capital Management, Llc | 31 Dec 2024 | 1,602,200 |
| Parkman Healthcare Partners Llc | 31 Dec 2024 | 1,273,789 |
| 52 Weeks Range | ||
| Median | 25.00 (153.29%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 07 Aug 2025 | 25.00 (153.29%) | Buy | 9.28 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Aug 2025 | Announcement | Arcus Biosciences to Participate in Three Upcoming Investor Conferences |
| 24 Jul 2025 | Announcement | Arcus Biosciences Announces New Employment Inducement Grants |
| 10 Jul 2025 | Announcement | Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer |
| 09 Jul 2025 | Announcement | Arcus Biosciences Announces New Employment Inducement Grants |
| 24 Jun 2025 | Announcement | Arcus Biosciences Announces New Employment Inducement Grants |
| 10 Jun 2025 | Announcement | Arcus Biosciences Announces New Employment Inducement Grants |
| 01 Jun 2025 | Announcement | Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |